Kyungdong Pharmaceutical and Owl Bio have announced that their long-acting obesity drug candidate AUL009 will be presented at the American Diabetes Association (ADA) 2026 meeting. The study, selected as a Late-Breaking Abstract, will disclose pharmacokinetic (PK) and safety data from a human trial. For overseas buyers and distributors, this signals a potential shift toward monthly-dosing GLP-1 injectables, which could reshape supply chains for obesity treatments.
Drug profile and platform
AUL009 is a semaglutide-based injectable using Owl Bio's Xtina long-acting drug delivery platform. Unlike current weekly semaglutide products, it is designed to maintain therapeutic effect for approximately one month after a single injection. The platform aims to improve patient compliance by reducing injection frequency.
Clinical data highlights
In a randomized trial in adult males, a single dose of AUL009 maintained stable blood drug concentrations for over 30 days. The formulation suppressed the initial burst effect common in long-acting injectables, potentially lowering early gastrointestinal side effects such as nausea and vomiting. The use of a 27-gauge ultra-fine needle also reduces injection pain compared to typical long-acting formulations.
Regulatory and channel signals
The ADA 2026 presentation provides international academic validation for AUL009's PK and safety profile. Both companies plan to accelerate global market entry and partnership expansion. Kyungdong Pharma stated the data will strengthen global competitiveness and commercialization foundations. Owl Bio aims to pursue technology transfer and strategic collaboration with global pharmaceutical companies.
What buyers should watch
For distributors and clinics, monthly-dosing GLP-1 products could reduce inventory turnover frequency and improve patient adherence. The 27G needle design may appeal to patient comfort, potentially driving demand in aesthetic and weight management clinics. However, the product remains in early clinical stages; regulatory approvals and manufacturing scale-up are key milestones to monitor.
Source: Read the original report | Published: June 11, 2026